The Resistance Mechanism of Trastuzumab Deruxtexan in HER2 Positive Breast Cancer Patients.

Last updated: March 19, 2024
Sponsor: Samsung Medical Center
Overall Status: Active - Recruiting

Phase

N/A

Condition

N/A

Treatment

GeoMx data analysis with clinical outcome

Clinical Study ID

NCT06330012
GeoMx_Breast
  • Female
  • Accepts Healthy Volunteers

Study Summary

This study is the spatial transcriptomic approach for revealing the resistance mechanism of trastuzumab deruxtexan in HER2 positive breast cancer patients.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • HER2 positive breast cancer
  • Stage IV disease
  • Treated with T-Dxd
  • Available FFPE samples

Exclusion

Exclusion Criteria:

  • TNBC breast cancer
  • Hormone receptor positive breast cancer
  • Non-available FFPE samples
  • Treated except T-Dxd

Study Design

Total Participants: 50
Treatment Group(s): 1
Primary Treatment: GeoMx data analysis with clinical outcome
Phase:
Study Start date:
March 18, 2024
Estimated Completion Date:
December 31, 2027

Connect with a study center

  • Ji-Yeon Kim

    Seoul, 06351
    Korea, Republic of

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.